Azoospermia (the absence of spermatozoa in the ejaculate after centrifugation) is identified in about 1,0 % of men in the general population and in 10–15 % of men seeking medical evaluation for infertility [1][2]. Timely differentiation between obstructive azoospermia (OA) and non-obstructive azoospermia (NOA) determines the management strategy, including microsurgical testicular sperm extraction (TESE) followed by intracytoplasmic sperm injection (ICSI), hormonal therapy in cases of hypogonadism, use of assisted reproductive technologies (ART), and assessment of future fertility potential with appropriate genetic counseling [1][3][4].

Current international guidelines proposed by the European Association of Urology (EAU, 2024), the American Urological Association/American Society for Reproductive Medicine (AUA/ASRM, 2024), and the World Health Organization (WHO, 2021) provide a standardized algorithm for managing such patients. However, they insufficiently address the distinct forms of non-obstructive azoospermia (hypogonadotropic and hypergonadotropic) which can markedly influence clinical decision-making and treatment strategy [1][3][5].

The modern azoospermia classification includes the following categories [1][3]:

In clinical practice, NOA is more frequently represented by testicular forms rather than pre-testicular (hypogonadotropic) variants, with proportions varying across cohorts from 40 to 60 %.

The modern diagnostic algorithm for evaluating men with azoospermia includes the following steps:

Domestic reviews and case series highlight common diagnostic pitfalls in differentiating OA from NOA and emphasize the importance of an integrated approach (hormonal assessment + ultrasonography + genetic testing + testicular biopsy when indicated) [11]. Russia-wide studies also report a significant proportion of CFTR-associated CBAVD, supporting the need for routine CFTR testing in this patient cohort [12].

Obstructive azoospermia occurs in approximately 30–40 % of men with azoospermia and is characterized by preserved spermatogenesis with impaired sperm transport. One of the key causes of OA is congenital bilateral absence of the vas deferens (CBAVD), considered a “genital form of cystic fibrosis” [1][2]. Up to 80–90 % of men with CBAVD carry mutations in the CFTR gene, located on chromosome 7q31.2 [2][3]. The most common variants include ΔF508, the 5T/7T/9T polymorphism in intron 8 (IVS8-5T), R117H, and W1282X [3][4].

Pubertal development and secondary sexual characteristics are typically normal. Ejaculate volume is often reduced (< 1.5 mL), with acidic pH (< 7.2), and fructose lacked in the ejaculate. On physical examination, the vas deferens is not palpable, frequently accompanied by bilateral agenesis of the seminal vesicles, which is confirmed by TRUS or magnetic resonance imaging (MRI) [5]. Spermatogenesis is preserved: testicular volume and FSH levels are generally within normal ranges.

Confirmed by physical examination (absence of the vas deferens) and imaging methods (TRUS – agenesis of the seminal vesicles, cysts); CFTR genetic testing is mandatory. Modern diagnostic panels include more than 30 variants, as the mutation spectrum varies across ethnic groups [2][6]. Russian cohorts demonstrate a high frequency of the ΔF508 mutation (a 3-nucleotide deletion in CFTR resulting in the loss of phenylalanine at position 508 the most common pathogenic variant) and the IVS8-5T allele (a variant in intron 8 of CFTR impairing mRNA splicing), as well as several rare variants, which justifies the use of extended sequencing approaches [7][8].

Men with CBAVD may be clinically healthy but they carry CFTR mutations. Partner testing is essential: if both partners carry pathogenic variants, the risk of having a child with cystic fibrosis is 25 % [1][2]. Upon such risk, preimplantation genetic testing within ART programs is recommended.

Because spermatogenesis is preserved, spermatozoa can be obtained with high efficiency using percutaneous epididymal sperm aspiration (PESA), microsurgical epididymal sperm aspiration (MESA), or testicular sperm extraction (TESE). The use of ICSI allows achieving reproductive outcomes comparable to those in men without CBAVD [9]. Long-term outcomes regarding the birth of healthy children are favorable, provided that appropriate genetic counseling is performed and bilateral carrier status in the female partner is excluded [2][9].

Male post-infectious and post-traumatic lesions in reproductive tract are among the most common causes of obstructive azoospermia. Damage or scarring of the vas deferens or epididymis may result from inflammatory diseases (epididymitis, orchiepididymitis, prostatitis, vesiculitis) caused by bacterial pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, ets., as well as genital tuberculosis. Post-inflammatory fibrosis of the epididymis or vas deferens leads to impaired sperm transport despite preserved spermatogenesis.

Post-traumatic obstruction may occur after surgical procedures in the inguinal region (hernia repair, vasectomy, scrotal surgery, prostate or bladder surgery), or after pelvic or scrotal trauma. In some patients, infectious–inflammatory and traumatic factors coexist.

Diagnosis is based on medical history, palpation of the epididymis (induration, enlargement, tenderness), ultrasonographic imaging, and biochemical analysis of the ejaculate (low volume, decreased pH, absence of fructose in cases involving seminal vesicles). When required, vasography or microsurgical reproductive ducts exploration is performed.

Surgical treatment includes microsurgical reconstruction of the reproductive tract (vasoepididymostomy, vasovasostomy). When reconstruction is not feasible or is unsuccessful, sperm retrieval techniques (PESA, MESA) followed by ART are utilized [2].

Hypergonadotropic (primary) hypogonadism is one of the leading causes of NOA and is characterized by azoospermia, elevated FSH/LH levels, and low serum testosterone and inhibin B [1][4][10].

Klinefelter syndrome (KS) is the most common chromosomal cause of male infertility, with a prevalence of ~1:600–1:800 male births [5]. More than 90 % of affected individuals present with NOA due to progressive atrophy and sclerosis of the seminiferous tubules. In mosaic forms (47,XXY/46,XY), the phenotype is milder, and severe oligozoospermia or cryptozoospermia may be found. In young adults (20–30 years), micro-TESE enables sperm retrieval in approximately 30–50 % of cases [6][7].

De la Chapelle syndrome (46,XX testicular disorders of sex development) is a rare form of sex-development disorder caused by translocation of the SRY gene (sex-determining region Y) onto the X chromosome in 46,XX males [8]. The estimated prevalence is ~1:20,000–25,000 male births.

The phenotype typically includes normal male external genitalia, small testes, hypergonadotropic hypogonadism, and infertility. Severe spermatogenic failure is characteristic, often presenting as a Sertoli-cell-only syndrome. Diagnosis is based on karyotyping (46,XX) and molecular testing for SRY. In most cases, treatment includes testosterone replacement therapy. Virtually no potential for sperm retrieval via TESE is reported [8].

Reifenstein syndrome results from mutations in the AR gene (androgen receptor) and manifests with varying degrees of androgen resistance [9]. The classic phenotype includes hypospadias, micropenis, cryptorchidism, gynecomastia, and reduced body hair. The karyotype is typically 46,XY, but the degree of virilization varies widely. In reproductive age, most affected men exhibit hypergonadotropic hypogonadism and azoospermia. Lifelong endocrine follow-up and andrological management are essential. Testosterone therapy corrects no the underlying defect and is generally ineffective [9].

Microdeletions within the AZF regions of the Y chromosome are among the most common genetic causes of male infertility and NOA.

AZFa deletions are most often associated with a Sertoli cell-only syndrome phenotype, making sperm retrieval by TESE virtually impossible and the prognosis extremely poor.

AZFb deletions typically present with complete meiotic arrest; the chance of successful sperm retrieval is also minimal.

AZFc deletions show substantial phenotypic variability, ranging from severe oligozoospermia to azoospermia. This group has the highest likelihood of successful surgical sperm retrieval (TESE), with reported success rates averaging up to 50 % in large studies.

However, sperm obtained from men with AZFc deletions transmit the same microdeletion to male offspring when used in ICSI, accounting for conducting mandatory thorough genetic counseling for couples [2][10–12].

Russian studies report Y-microdeletion prevalence among men with pathozoospermia to be about 15–20%, varying depending on patient selection criteria [13][14].

Persistent Müllerian duct syndrome (PMDS) is a rare autosomal recessive disorder in which Müllerian duct derivatives (uterus, fallopian tubes, upper vagina) persist in genetically and phenotypically male individuals (46,XY). The primary cause is mutations in the AMH (anti-Müllerian hormone) gene or the AMHR2 (anti-Müllerian hormone type 2 receptor) gene, resulting in absent or ineffective AMH activity [15]. The karyotype is 46,XY, with normal development of the external genitalia. The most common manifestation is unilateral or bilateral cryptorchidism, frequently accompanied by developing inguinal or abdominal masses. During surgical treatment for cryptorchidism, Müllerian structures (uterus/tubes) are often identified.

In some patients, hypergonadotropic hypogonadism develops due to testicular damage caused by cryptorchidism and fibrosis, with profound spermatogenic impairment and common secretory azoospermia. PMDS is suspected when cryptorchidism is combined with pelvic masses. Diagnosis is confirmed by laparoscopy and histological examination.

Due to cryptorchidism and testicular tissue damage, most patients exhibit severely impaired spermatogenesis. The likelihood of retrieving sperm via TESE is extremely low. The primary management goals include surgical removal of Müllerian structures (when there is a risk of malignancy), orchiopexy, and testosterone replacement therapy for hypogonadism [15].

Idiopathic cryptorchidism is a pathological condition in which one or both testes fail to descend into the scrotum, with prevalence comprising 2–4 % and up to 30 % in full-term newborns and preterm infants, respectively, although in most cases spontaneous descent occurs within the first year of life. Persistent cryptorchidism is observed in about 1.0 % of adult men [16].

Idiopathic cryptorchidism is diagnosed when no genetic or anatomical cause can be identified. It is considered a polyetiological disorder resulting from impaired testicular differentiation and migration [16]. Prolonged cryptorchidism leads to progressive damage to the spermatogenic epithelium. As early as 1–2 years of age, undescended testes show a reduced spermatogonia count. In adulthood, 30–60 % of men with untreated bilateral cryptorchidism develop NOA. In unilateral cases, the risk of infertility is lower, but approximately 20 % of patients exhibit reduced fertility despite a normal contralateral testis [16].

Adult men with cryptorchidism frequently present with hypergonadotropic hypogonadism (elevated FSH, reduced inhibin B), reflecting loss of spermatogenesis. Clinical trials indicate that 50–70% of men with bilateral cryptorchidism have azoospermia, while the remainder exhibit severe oligozoospermia [16]. Early orchiopexy (before 12–18 months of age) significantly improves the likelihood of preserving spermatogenesis. In adults with idiopathic cryptorchidism, the fertility-enhancing effect of orchiopexy is limited. The probability of successful sperm retrieval via TESE in men with untreated bilateral cryptorchidism remains low (10–30 %), although in selected cases fertilization via ICSI is achievable [16].

Autoimmune orchitis is a chronic testicular inflammatory disorder associated with the production of antibodies targeting antigens of spermatogenic cells (anti-testicular antibodies). Under normal conditions, spermatozoa are immunologically protected by the blood–testis barrier; however, infections (mumps, tuberculosis, human papillomavirus), trauma, scrotal surgeries, varicocele, and systemic autoimmune diseases can disrupt this barrier and trigger an autoimmune response [17].

Clinical manifestations / Клинические проявления

Primary infertility is the most common presentation. Hypergonadotropic hypogonadism (elevated FSH and LH, low testosterone) is typical. Medical history often includes episodes of epididymo-orchitis, trauma, or prior scrotal surgery. Occasionally patients report testicular pain or enlargement, but in most cases the disease is subclinical [17].

Diagnostics / Диагностика

Prognosis and treatment / Прогноз и лечение

TESE is generally ineffective in the presence of pronounced testicular fibrosis. In selected cases, cryopreservation of spermatozoa may be possible during early disease stages. When spermatozoa are present in the ejaculate, ICSI is the method of choice, as antisperm antibodies markedly impair natural fertilization [17]. Glucocorticoid therapy may temporarily reduce antibody levels, but its clinical efficacy is limited. Immunomodulators and antioxidant therapy are used, although the evidence base is weak. For most patients, ART programs (ICSI) represent the primary route to biological fatherhood [17].

Varicocele is a common finding in infertile men. In some patients with NOA and clinical varicocele, micro-surgical correction may lead to the reappearance of spermatozoa in the ejaculate and improved pregnancy rates, including following TESE [18][19]. Meta-analyses report the return of ejaculated sperm in approximately 20–45 % of men with NOA after varicocelectomy, along with an increased rate of conception (spontaneous or ART-assisted) compared with observation alone [15]. Russian reviews confirm clinical benefit in this patient subgroup [20][21].

Varicocele is diagnosed in ~15–20% of men in the general population and in 30–40 % of infertile patients [1]. In Klinefelter syndrome, its prevalence reaches 20–25 % according to various series [5]. In КS patients,spermatogenic impairment is primarily attributed to chromosomal aneuploidy and seminiferous tubule atrophy. Nonetheless, varicocele may exacerbate local hyperthermia, oxidative stress, and apoptosis of spermatogenic cells, further reducing the likelihood of successful sperm retrieval during micro-TESE [5].

A few studies report that although varicocele does not modify the core pathogenic mechanism of infertility in KS, its correction may provide limited improvement in testicular function. Among young patients (mosaic karyotype or residual spermatogenesis), isolated cases of ejaculated sperm appearance have been documented after varicocelectomy, facilitating subsequent ICSI attempts. However, there is no systematic evidence showing substantial improvement in ART outcomes following varicocele repair in KS.

Most experts agree that surgical correction of varicocele in KS is justified only in the presence of prominent clinical symptoms (pain, progressive testicular atrophy), but not as a fertility-restoring intervention [5].

In Russian patient series, varicocele was present in 18–20 % of men with KS. Surgical treatment was performed in a limited number of cases and did not restore spermatogenesis but alleviated pain and slow testicular atrophy progression [22].

Congenital and acquired hypogonadotropic hypogonadism (HGG) is characterized by insufficient secretion of gonadotropins (FSH and LH) due to dysfunction of the hypothalamic–pituitary axis. This results in decreased testosterone production by Leydig cells and impaired spermatogenesis, often progressing to azoospermia. Unlike hypergonadotropic hypogonadism, HGG manifests with low or “inappropriately normal” FSH/LH levels and reduced testosterone.

The form of the disorder accompanied by anosmia is known as Kallmann syndrome. Its etiology involves mutations in genes such as KAL1 (Kallmann syndrome 1 sequence gene), FGFR1 (fibroblast growth factor receptor 1), PROKR2 (prokineticin receptor 2), CHD7 (chromodomain helicase DNA-binding protein 7), among others, which disrupt the migration and/or function of gonadotropin-releasing hormone (GnRH)-secreting neurons [23].

Men with HGG/Kallmann syndrome typically present with azoospermia, but 60–70 % can achieve spermatogenesis with prolonged gonadotropin therapy – human chorionic gonadotropin (hCG) with or without recombinant FSH or with pulsatile GnRH administration.

Acquired vs. congenital HGG is more common and may develop at any age. The main causes include:

Diagnosis is based on low or “inappropriately normal” FSH/LH levels in the presence of low testosterone. A lack of gonadotropin elevation after GnRH stimulation points at the central defect. Pituitary MRI is mandatory to exclude tumours.

Unlike hypergonadotropic hypogonadism, congenital and acquired HGG are fundamentally distinct in that spermatogenesis can be stimulated with relevant therapy [23]. In 60–70 % of men, spermatogenesis can be induced using gonadotropin therapy (hCG ± FSH) or pulsatile GnRH administration [23].

In HGG, hCG monotherapy stimulates Leydig cells and increases testosterone, but spermatogenesis typically is not initiated without FSH. The addition of FSH (urinary or recombinant) is essential for Sertoli cell stimulation and induction of meiosis [23]. FSH preparations: urinary FSH (containing both FSH and LH) and recombinant FSH (follitropin alfa, follitropin beta). Typical regimen: treatment begins with hCG (1500–2500 IU twice weekly) to normalize testosterone. If no spermatozoa appear following 3–6 months, FSH (75–150 IU three times weekly) is added. Total duration: 6–24 months, sometimes longer. In men with congenital or acquired HGG, successful induction of spermatogenesis is achieved in 60–80 % of cases [23]. The mean time to spermatozoa appearance in the ejaculate is 6–12 months. FSH is the key hormone in HGG therapy: without it, complete recovery of spermatogenesis is impossible. Predictors of successful FSH-based treatment in HGG-associated azoospermia larger baseline testicular volume (> 8 mL), absence of former cryptorchidism, shorter duration of hypogonadism in acquired hypopituitarism, spontaneous pubertal development [23].

Altogether, such considerations underscore the relevance of studying patient cohorts from endocrinology centers in Saint Petersburg and Tashkent to identify a target group of infertile men managed jointly by endocrinologists and urologists-andrologists in real-world clinical practice.

Aim: to investigate the prevalence of different azoospermia forms in infertile men, within the context of real-world clinical practice at a non-specialized endocrine outpatient department, including personal observations, in comparison with the results of international and Russian epidemiological studies.

To achieve this aim, it is necessary to summarize current epidemiological data on the prevalence of different azoospermia forms, analyze personal findings after assessing patients with azoospermia and compare them with international and Russian data, and to develop a practical algorithm for the differential diagnosis of azoospermia for routine clinical use by urologists, endocrinologists, and reproductive specialists.

The retrospective cohort observational study enrolled 450 men aged 25 to 45 years who presented with complaints of infertility, with azoospermia confirmed by semen analysis. Examination and treatment were carried out at the following centers: MEDSI Group Clinic (Saint Petersburg, Russia), Center for Academic Medicine LLC (Saint Petersburg, Russia), Genotechnology LLC (Tashkent, Republic of Uzbekistan), and Andijan State Medical Institute (Andijan, Republic of Uzbekistan).

Inclusion criteria: age 25–45 years; clinical diagnosis of infertility (no pregnancy in the partner after ≥ 12 months of regular unprotected sexual intercourse); azoospermia confirmed by at least two semen analyses; written informed consent to participate in the study.

Exclusion criteria: age < 25 or > 45 years; prior vasectomy or other surgical interventions intentionally causing obstruction; severe somatic or oncological disease precluding full evaluation; refusal to participate in the study.

All patients underwent a comprehensive evaluation including:

– detailed medical history (reproductive, general medical, surgical);

– physical examination by assessing secondary sexual characteristics, testicular size and consistency; duplicate semen analysis (centrifugation and microscopy) performed according to the WHO methodology [1]; serum hormone quantitation: FSH, LH, total testosterone, prolactin, AMH, sex hormone–binding globulin (SHBG), inhibin B; when indicated – estradiol, thyroid-stimulating hormone (TSH), thyroxine (T4), and hCG; scrotal ultrasonography with Doppler assessment;

– genetic testing: karyotyping, screening for AZF microdeletions of the Y chromosome, and CFTR gene analysis when congenital absence of the vas deferens was suspected;

– within ART programs: testicular biopsy (TESE/micro-TESE) with histological examination and sperm cryopreservation.

Based on the results from the comprehensive evaluation, all 450 patients were classified into diagnostic groups presented in Table 1.

The data obtained confirm that non-obstructive azoospermia predominates in this cohort (63.3 %), which is consistent with international reports (60–70 %) [2][5][10]. Among NOA cases, idiopathic NOA accounted for the largest percentage (19.6 %), slightly lower than global estimates of 30–40 % [2].

Genetic causes were identified in a substantial number of patients. Klinefelter syndrome was diagnosed in 8.4 %, consistent with large cohort studies reporting 8–10 % [6]. Y-chromosome microdeletions were found in 5.8 % of men – slightly below the international range (8–12 %) [7], likely due to ethnic factors and limitations of the marker panel used. Rare etiologies – de la Chapelle syndrome (2.2 %), Reifenstein syndrome (1.8 %), and persistent Müllerian duct syndrome (0.9 %) were less prevalent, yet remain critically important for accurate diagnosis and genetic counseling.

A history of cryptorchidism was recorded in 9.3 % of patients, aligning with published data (9–10 %) [21]. Autoimmune orchitis accounted for 3.3 %, some higher than the expected 2–3 % [22], possibly reflecting variability in diagnostic criteria, as detection of anti-testicular antibodies is not always reliable. Varicocele associated with NOA was observed in 12 %, consistent with its known prevalence among infertile men [16][17].

Obstructive azoospermia was somewhat less common in our study (30 %) than in a number of international publications (up to 40 %) [1][2]. Among OA etiologies, post-infectious or post-traumatic obstruction predominated (29.6 %). CFTR-associated CBAVD was identified in only 0.4 % of patients, below the international estimate of 1–2 % [7][8], potentially due to restricted genetic testing or population-specific factors.

Hypogonadotropic hypogonadism was found in 6.7 % of men, exceeding typical published studies (2–5 %) [5]. Both congenital forms (Kallmann syndrome – 2.7 %) and acquired forms (hyperprolactinemia, post-traumatic hypopituitarism) were represented, underscoring the need for thorough neuroendocrine evaluation in men with azoospermia [23].

Thus, the results confirm that azoospermia is a clinically and etiologically heterogeneous condition. The data for our patient cohort are consistent with global trends, but the discrepancies identified (a higher proportion of HGG, a slightly lower frequency of CFTR-associated CBAVD and Y microdeletions) may reflect population characteristics and methodological differences.

Based on conducted study of men with azoospermia, taking into account international data, we developed an algorithm for examining men with azoospermia, which we present to readers.

{A} Azoospermia or oligozoospermia must be assessed only after excluding medication use that affects the reproductive system, chronic intoxications, and occupational hazards. In cases of azoospermia, differential diagnosis with obstructive azoospermia is essential, particularly in men with a history of epididymo-orchitis, vasectomy, or cystic fibrosis. Measurement of α-glucosidase (and fructose) in the ejaculate is helpful, as it is markedly reduced in obstruction.

{B} In this situation, it is necessary to differentiate among the various forms of hypogonadotropic hypogonadism. In most cases these represent congenital disorders, including idiopathic hypogonadotropic hypogonadism and Kallmann syndrome (when anosmia is present). However, hypogonadism may also result from tumors or malformations of the hypothalamic–pituitary region. If a craniopharyngioma or another neoplasm is diagnosed, neurosurgical intervention may be required.

{C} Hyperprolactinemia and prolactin-secreting pituitary adenoma (prolactinoma) are fairly common causes of male infertility. Treatment with dopamine receptor agonists (cabergoline, bromocriptine) leads to normalization of sexual function and restoration of spermatogenesis. In resistant cases, neurosurgical management may be necessary.

{D} Testicular tumors producing estrogens or hCG are increasingly encountered among men seeking medical attention for infertility. Progressive tumor growth within the testis suppresses spermatogenesis and disrupts steroidogenesis, leading to sexual dysfunction and infertility. Sperm cryopreservation is recommended, as subsequent treatment may further impair germinal epithelium or necessitate gonadectomy (in some cases, bilateral).

{E} In this case, the cause of infertility is hypergonadotropic hypogonadism, which may result from congenital (e.g., karyotype abnormalities) or acquired factors. Among the latter, scrotal disorders that provoke testicular atrophy are most prominent, including varicocele, hydrocele, trauma, and testicular torsion.

{F} Isolated elevation of FSH in infertile men most often indicates isolated damage to the germinal epithelium (spermatogenesis), which may result from both congenital and acquired causes. In congenital forms, impaired spermatogenesis is most commonly associated with Y-chromosome microdeletions (AZF gene deletions). Acquired forms of spermatogenic dysfunction are more often related to developing autoimmune process in the testes – autoimmune orchitis or to testicular damage resulting from varicocele or hydrocele.

{G} A twofold increase in estradiol levels or elevated hCG in the blood indicates a possible testicular tumor, which manifests with gynecomastia, reduced sexual desire, and infertility (oligozoospermia or azoospermia).

{H} Dopaminergic receptor agonists allow for to normalizing serum prolactin levels and restore spermatogenesis. If no recovery occur, the cause of infertility may be due to accompanying pituitary adenoma (more commonly a macroadenoma), development of hypogonadotropic hypogonadism, or a combination with other factors.

{I} Klinefelter syndrome most often presents clinically with infertility of varying severity: from azoospermia and hyalinization of the seminiferous tubules to oligozoospermia. Even cases of normozoospermia have been described. However, pharmacological treatment options for Klinefelter syndrome are not available. Sperm cryopreservation and ART are indicated to overcome infertility.

{J} De la Chapelle syndrome is a rare cause of male infertility, but such patients may present in the practice of endocrinologists, andrologists, and reproductive specialists. In most cases, men with a 46,XX karyotype have severe spermatogenic dysfunction: azoospermia, hyalinization of the seminiferous tubules, and treatment of such infertility is not feasible. Testicular biopsy is not recommended in these patients for sperm retrieval.

{K} Microdeletions of the Y chromosome are a common finding in infertile men. Loss of the critical AZF region essential for spermatogenesis leads to infertility. Pharmacological treatments are not available. ART are indicated. In patients with azoospermia, testicular biopsy (TESE) is recommended to attempt sperm retrieval.

{L} In patients with normal gonadotropin levels, differential diagnosis between OA and NOA is required. Measurement of α-glucosidase and fructose in the ejaculate may assist in diagnosis. Genetic testing for CFTR mutations is also indicated, as cystic fibrosis may cause infertility. The mechanism of OA formation relies on congenital underdevelopment of the vas deferens. Treatment of infertility is possible only with ART (IVF). Sperm retrieval is performed using TESE. If OA is caused by acquired obstruction, fertility may be restored surgically by reconstructive repair of the vas deferens.

{M} Treatment of infertility in hypogonadotropic hypogonadism requires the use of FSH and hCG. The duration of therapy is at least 1 year. Complete restoration of spermatogenesis has been demonstrated in these patients. However, treatment failure occurs in about 10 % of cases.

{N} Pharmacotherapy for infertility in patients with hypergonadotropic hypogonadism has not been developed. In most cases, ART is required, so that male patients should undergo sperm cryopreservation.

{O} Testosterone replacement therapy in men with hypogonadism is lifelong. Testosterone preparations suppress FSH production in the anterior pituitary and may worsen semen parameters. Therefore, sperm cryopreservation is recommended before onset of androgen replacement therapy.

{P} Assisted reproductive technologies allow infertility to be overcome in the majority of male reproductive disorders. However, the choice of method depends on the expertise of the reproductive center, its technical capabilities, and the patient’s specific diagnosis. If sperm retrieval is unsuccessful, donor sperm is indicated. Genetic testing and counseling of the couple are recommended in most ART cases.

Among the 450 men with azoospermia, the non-obstructive form predominated (63.3%), with idiopathic NOA being the most frequent subtype. Genetic factors (Klinefelter syndrome, Y-chromosome microdeletions, and rare disorders of sex development) were identified in nearly one out of six patients, confirming the need for mandatory genetic testing in the diagnostic algorithm for azoospermia. Obstructive azoospermia (30 %) was most often associated with post-infectious and post-traumatic changes, whereas CBAVD associated with CFTR mutations was less common than in international cohorts. The proportion of hypogonadotropic hypogonadism was higher than expected (6.7 %), underscoring the importance of comprehensive hormonal evaluation in all men with azoospermia.

Altogether, our results agree with international data but highlight certain regional characteristics that should be taken into consideration while developing national clinical guidelines.